Suppr超能文献

通过基于性别、年龄、身高和体重的肝素方案实现目标抗Xa因子活性。

Achieving target antifactor Xa activity with a heparin protocol based on sex, age, height, and weight.

作者信息

Rosborough Terry K, Shepherd Michele F

机构信息

Medical Education Department, Abbott Northwestern Hospital, Minneapolis, Minnesota 55407, USA.

出版信息

Pharmacotherapy. 2004 Jun;24(6):713-9. doi: 10.1592/phco.24.8.713.36067.

Abstract

STUDY OBJECTIVES

To develop and validate an improved unfractionated heparin (UFH) dosage protocol, using antifactor Xa levels as the outcome variable.

DESIGN

Prospective case series.

SETTING

A 625-bed, adults-only private, tertiary care teaching hospital.

PATIENTS

Three hundred seventy-two patients receiving UFH for eight different indications were in the protocol derivation group. One hundred ninety-seven patients were in the final validation group. Intervention. Variables that predicted successful UFH treatment were determined by analysis of variance and regression.

MEASUREMENTS AND MAIN RESULTS

Sex, age, height, weight, UFH dosage, and antifactor Xa levels were variables. A regression model using sex, age, height, and weight was superior to a weight-only model in predicting UFH dosage. Target-range antifactor Xa levels were achieved with the new protocol in 122 (87%) of 140 patients within 24 hours of start of therapy.

CONCLUSION

A UFH dosage protocol based on patient sex, age, height, and weight produced improved initial target antifactor Xa levels compared with a weight-based protocol. The protocol is computerized and easy to apply.

摘要

研究目的

使用抗Xa因子水平作为结果变量,制定并验证一种改进的普通肝素(UFH)给药方案。

设计

前瞻性病例系列研究。

地点

一家拥有625张床位、仅收治成人患者的私立三级护理教学医院。

患者

372例因8种不同适应证接受UFH治疗的患者纳入方案推导组。197例患者纳入最终验证组。干预措施:通过方差分析和回归分析确定预测UFH治疗成功的变量。

测量指标及主要结果

性别、年龄、身高、体重、UFH剂量和抗Xa因子水平为变量。在预测UFH剂量方面,使用性别、年龄、身高和体重的回归模型优于仅使用体重的模型。新方案使140例患者中的122例(87%)在开始治疗后24小时内达到目标范围的抗Xa因子水平。

结论

与基于体重的方案相比,基于患者性别、年龄、身高和体重的UFH给药方案能提高初始目标抗Xa因子水平。该方案已实现计算机化,易于应用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验